Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
AZD-1940
Другие языки:

    AZD-1940

    Подписчиков: 0, рейтинг: 0
    AZD-1940
    AZD1940 structure.png
    Clinical data
    Routes of
    administration    		 Oral
    Legal status
    Legal status
    Identifiers
    • N-{1-[(4,4-difluorocyclohexyl)methyl]-2-(1,1-dimethylethyl)-1H-benzimidazol-5-yl}ethanesulfonamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    Chemical and physical data
    Formula C20H29F2N3O2S
    Molar mass 413.53 g·mol−1
    3D model (JSmol)
    • CCS(=O)(=O)Nc1ccc2c(c1)nc(n2CC3CCC(CC3)(F)F)C(C)(C)C
    • InChI=1S/C20H29F2N3O2S/c1-5-28(26,27)24-15-6-7-17-16(12-15)23-18(19(2,3)4)25(17)13-14-8-10-20(21,22)11-9-14/h6-7,12,14,24H,5,8-11,13H2,1-4H3
    • Key:ZAGGGZCIFUQHOH-UHFFFAOYSA-N

    AZD-1940 is a drug developed by AstraZeneca, that is a peripherally selective cannabinoid agonist which binds with high affinity to both the CB1 and CB2 receptors. It was developed for the treatment of neuropathic pain, but while it showed good peripheral selectivity in animal studies, in human clinical trials it failed to show sufficient analgesic efficacy and produced unexpectedly strong side effects associated with central cannabinoid activity, and so was discontinued from further development.

    See also


    Новое сообщение